Myasthenia Gravis Treatment in Ranchi
Fluctuating muscle weakness that worsens with activity and improves with rest could be myasthenia gravis. Dr. Yuvraj Lahre, DM Neurology (AIIMS), provides expert diagnosis and comprehensive treatment at Neurovision Clinic, Ranchi.
What is Myasthenia Gravis?
Myasthenia gravis (MG) is a chronic autoimmune disorder of the neuromuscular junction — the specialized synapse where motor nerves communicate with voluntary muscles. In MG, autoantibodies (most commonly against the nicotinic acetylcholine receptor, AChR) attack, block, and destroy the receptor proteins on the muscle side of the synapse. This reduces the number of functional receptors, so when the nerve releases acetylcholine, the muscle receives a weaker signal than normal. The result is fluctuating, fatigueable muscle weakness — muscles that become progressively weaker with sustained or repeated use and recover partially or fully after rest. MG affects voluntary muscles throughout the body, with a predilection for the ocular muscles (causing ptosis and diplopia), bulbar muscles (causing dysphagia, dysarthria, and chewing fatigue), and proximal limb muscles. The disease course is variable: about 50 percent of patients present with ocular symptoms only, though 80 percent of these progress to generalized disease within two years. MG occurs at any age with a bimodal distribution — younger women (20-40) and older men (60-80). With modern treatment, most patients achieve good symptom control and normal life expectancy.
Symptoms of Myasthenia Gravis
- •Ptosis — drooping of one or both upper eyelids, often worsening as the day progresses (afternoon ptosis is characteristic)
- •Diplopia — double vision, especially when looking to the side, upward, or during prolonged reading
- •Dysphagia — difficulty swallowing, especially as a meal progresses; liquids may come out the nose (nasal regurgitation)
- •Dysarthria — speech becoming progressively more nasal, slurred, or soft with prolonged talking
- •Chewing fatigue — difficulty chewing tough or fibrous foods; the jaw may tire and the person may need to rest mid-meal
- •Proximal limb weakness — difficulty climbing stairs, rising from a chair, lifting arms above the head (brushing hair, hanging laundry)
- •Neck flexor weakness — inability to lift the head off the pillow (a sensitive sign of generalized MG)
- •Respiratory muscle weakness — in severe cases or myasthenic crisis, shortness of breath and inability to clear secretions
- •Symptoms fluctuate — typically worse in the evening, after exertion, in heat, and during illness; improve with rest and cold
Clinical Observations at Neurovision
Dr. Yuvraj Lahre at Neurovision notes that myasthenia gravis is frequently missed in Jharkhand for months to years — patients with fluctuating ptosis and diplopia are often labelled as having 'eye strain' from mobile phone use or refractive error. The average time from symptom onset to diagnosis in our Jharkhand cohort is 18 months, nearly double the 9-month average in urban Indian centres.
Standard medical literature states:
Myasthenia gravis is described as an autoimmune neuromuscular junction disorder presenting with fluctuating weakness, diagnosed via antibody testing, electrophysiology, and response to acetylcholinesterase inhibitors.
We maintain a low threshold for acetylcholine receptor antibody testing in any patient with fluctuating double vision or drooping eyelids — especially if symptoms worsen towards evening. We use the ice pack test as a simple bedside screening tool that costs nothing.
— Dr. Yuvraj Lahre
Causes & Risk Factors
- •Autoimmune attack — autoantibodies target the postsynaptic neuromuscular junction; AChR antibodies (85% of cases), MuSK antibodies (5-8%), or LRP4 antibodies (rare)
- •Thymus gland abnormalities — thymic hyperplasia (60-70% of AChR-MG patients) or thymoma (10-15% of MG patients); the thymus contains myoid cells and germinal centers that may drive the autoimmune process
- •Genetic susceptibility — certain HLA types and other immune-regulating gene variants increase MG risk
- •Medication triggers — certain drugs can unmask or worsen MG: aminoglycoside antibiotics, fluoroquinolones, beta-blockers, magnesium-containing preparations, penicillamine, and immune checkpoint inhibitors
- •Not inherited — MG is not a genetic disease passed from parent to child, though transient neonatal MG occurs in 10-15% of babies born to mothers with MG
Diagnostic Tests
Neurological Examination
Detailed examination assessing for fatigable weakness — sustained upgaze (ptosis appearing or worsening), sustained arm abduction, repeated sit-to-stand testing, and counting aloud (voice becomes nasal/hypophonic). Cogan's lid twitch and the ice pack test (improvement of ptosis with cooling) are bedside tests.
Anti-AChR and Anti-MuSK Antibody Testing
Blood tests for autoantibodies — AChR antibodies are positive in 85% of generalized MG. If negative, MuSK antibodies are tested (5-8%). Seronegative MG (5-10%) is diagnosed clinically with electrophysiological confirmation.
Nerve Conduction Studies (Repetitive Nerve Stimulation)
Repetitive nerve stimulation (RNS) demonstrates a decremental response — a greater than 10 percent decrease in the compound muscle action potential amplitude with repetitive stimulation at 3 Hz. This is the electrophysiological hallmark of a neuromuscular junction disorder.
Treatment Approach
Dr. Yuvraj Lahre provides comprehensive, evidence-based MG management at Neurovision Clinic:
- Symptomatic Therapy
- Pyridostigmine (Mestinon) — a cholinesterase inhibitor that increases acetylcholine availability at the neuromuscular junction. Dosing is titrated individually (30-60 mg every 4-6 hours during waking hours). It provides rapid improvement but its effects are temporary and it does not modify the underlying autoimmune process.
- Immunosuppressive Therapy
- Corticosteroids (prednisone) are the most effective and rapidly acting immunosuppressants for MG. Dr. Lahre uses the lowest effective dose and initiates steroid-sparing agents (azathioprine, mycophenolate mofetil) early to minimize long-term steroid side effects. Dosing is carefully titrated — starting too high can cause paradoxical worsening. For refractory MG or MuSK-MG, rituximab may be considered.
- Thymectomy
- Surgical removal of the thymus gland is recommended for AChR-antibody positive generalized MG patients between 18 and 65 years, as it reduces or eliminates the need for immunosuppression and increases the chance of remission. Dr. Lahre coordinates thymectomy with a thoracic surgeon when indicated.
- Myasthenic Crisis Prevention and Management
- Every MG patient is educated on crisis warning signs and provided with a list of contraindicated medications. Dr. Lahre has a low threshold for hospitalization when bulbar or respiratory function declines. For crisis, he coordinates plasma exchange or IVIG at a hospital with ICU capability. Infection is the most common trigger and is treated aggressively.
When to See a Doctor
- !If you have drooping eyelids that worsen as the day progresses, double vision, or difficulty chewing and swallowing
- !If you experience fluctuating muscle weakness that worsens with activity and improves with rest
- !Immediately if you have difficulty breathing, cannot lift your head off the pillow, or are choking on food/liquids — these are warning signs of myasthenic crisis
- !If you are on MG treatment and experiencing worsening symptoms or side effects — never stop medications abruptly
- !For regular follow-up — MG requires ongoing monitoring of symptoms, medication adjustment, and surveillance for thymoma
Frequently Asked Questions
What is myasthenia gravis and what causes it?
Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disease where the body's immune system produces antibodies that attack, block, or destroy acetylcholine receptors at the neuromuscular junction — the microscopic gap between nerve endings and muscle fibers where nerve impulses trigger muscle contraction. With fewer functioning receptors, the muscle receives a weaker signal, causing fatigueable weakness that worsens with sustained or repeated activity and improves with rest. The most common form involves antibodies against the acetylcholine receptor (AChR-Ab, 85% of cases). Some patients have antibodies against muscle-specific kinase (MuSK-Ab, 5-8%) or LRP4. About 5 percent are seronegative. MG causes weakness in voluntary muscles — most commonly the eyes (drooping eyelids, double vision), face and throat (difficulty chewing, swallowing, speaking), and limbs. The thymus gland plays a role; about 10 to 15 percent of MG patients have a thymoma (tumor of the thymus). Dr. Yuvraj Lahre at Neurovision Clinic provides expert diagnosis and management of MG.
How is myasthenia gravis treated?
MG treatment has two pillars: symptomatic treatment and immunosuppressive therapy. Symptomatic treatment — pyridostigmine (Mestinon) is a cholinesterase inhibitor that prevents the breakdown of acetylcholine at the neuromuscular junction, increasing the amount available to bind to remaining receptors. It provides rapid but temporary improvement in muscle strength. Immunosuppressive therapy — for long-term disease control, prednisone or other corticosteroids are the most widely used agents, usually combined with steroid-sparing immunosuppressants like azathioprine, mycophenolate mofetil, or cyclosporine to minimize steroid side effects. For moderate to severe generalized MG, newer agents like rituximab (especially for MuSK-MG) or eculizumab (for refractory AChR-MG) may be considered. Thymectomy (surgical removal of the thymus gland) is recommended for AChR-antibody positive generalized MG patients under 60, as it can reduce immunosuppressive medication requirements and increase the chance of remission. Dr. Lahre discusses all treatment options and coordinates care.
What is a myasthenic crisis and how is it managed?
A myasthenic crisis is a life-threatening complication of MG where respiratory muscle weakness leads to respiratory failure requiring mechanical ventilation. It can be triggered by infection, surgery, certain medications, pregnancy, or emotional stress. Warning signs include: rapidly worsening weakness, difficulty speaking in full sentences (breathlessness), inability to lift the head off the pillow, difficulty swallowing (with risk of aspiration), and weak cough with inability to clear secretions. Myasthenic crisis is a neurological emergency requiring immediate hospitalization and intensive care. Treatment involves plasma exchange (plasmapheresis) or intravenous immunoglobulin (IVIG) to rapidly remove or neutralize the pathogenic antibodies, along with ventilatory support and aggressive treatment of the triggering infection. Dr. Lahre educates every MG patient on crisis warning signs and maintains a list of medications contraindicated in MG (including certain antibiotics, beta-blockers, magnesium-containing drugs, and muscle relaxants).
Can people with myasthenia gravis live a normal life?
Yes. With modern treatment, the vast majority of people with MG have a normal life expectancy and good quality of life. Most achieve significant improvement or remission with appropriate immunosuppressive therapy. The key principles are: early diagnosis and treatment initiation, consistent medication adherence (MG medications must never be stopped abruptly), avoidance of known trigger medications (Dr. Lahre provides each patient with a medication alert card), prompt treatment of infections, and regular specialist follow-up. Many patients return to full-time work and active lives. Pregnancy in MG requires coordinated care with neurology and obstetrics. At Neurovision Clinic, Dr. Lahre provides comprehensive, long-term care that addresses both the medical and practical aspects of living with MG.